Kidney transplantation remains the optimal treatment for eligible patients with end-stage renal disease. However, the lifelong requirement for immunosuppressive therapy introduces significant risks of infection, malignancy, and cardiovascular complications. The standard triple maintenance regimen of calcineurin inhibitor (CNI), antimetabolite, and corticosteroid has remained largely unchanged for decades, despite the CNI nephrotoxicity well documented in serial allograft biopsies reported by Nankivell et al. in the New England Journal of Medicine (2003).
ISN (International Society of Nephrology) has published educational materials addressing the evolving landscape of transplant immunosuppression. The BENEFIT and BENEFIT-EXT trials (Vincenti et al., New England Journal of Medicine, 2010; and American Journal of Transplantation, 2016) demonstrated that belatacept-based maintenance, a selective T-cell costimulation blocker, produced superior renal function trajectories at five and seven years post-transplantation compared to cyclosporine-based regimens, establishing a CNI-sparing alternative for eligible recipients.
Advances in donor-specific antibody (DSA) monitoring have highlighted the humoral immune system as a central target for novel strategies against antibody-mediated rejection (AMR). The DESCARTES observational study and registries maintained by the Collaborative Transplant Study have defined the natural history of de novo DSA development and its association with chronic AMR and graft loss, providing the epidemiological basis for current monitoring recommendations in KDIGO transplant guidelines.
Complement inhibition with eculizumab has been reported as a rescue therapy for severe AMR in case series and small prospective studies published in Transplantation and American Journal of Transplantation. Proteasome inhibitors such as bortezomib, and anti-CD38 agents including daratumumab, represent investigational approaches targeting plasma cells responsible for DSA production, with early-phase study results reviewed in a Kidney International commentary (Schinstock et al., 2021).
The International Society of Nephrology has called for international collaboration in establishing biomarker-driven immunosuppression protocols. The Banff classification system, updated most recently in 2022 (Loupy et al., American Journal of Transplantation), provides the standardized histopathological framework for rejection phenotyping. ISN has supported the dissemination of Banff criteria internationally as an essential foundation for consistent trial design and clinical practice in kidney transplantation.